Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.
To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Platelet activating factor
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).
Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).
Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Madi S et al. | Allergen-induced bronchospasm in passively sensitized guinea pigs: influence of new substances in comparison to reference compounds. | 1991 | Agents Actions | pmid:2058463 |
Braquet P and Esanu A | New trends in PAF antagonist research: a new series of potent hetrapazine-derived PAF antagonists. | 1991 | Agents Actions | pmid:2058466 |
Northover AM | Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. | 1990 | Agents Actions | pmid:2111079 |
Desai S and Barton R | Role of platelet activating factor in the pathogenesis of active and passive models of experimental allergic encephalomyelitis in the rat. | 1990 | Agents Actions | pmid:2285021 |
Trebien HA and Calixto JB | Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. | 1989 | Agents Actions | pmid:2660497 |
Sanchez Crespo M and Nieto ML | Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. | 1989 | Agents Actions | pmid:2711927 |
Howat DW et al. | An investigation into the possible involvement of platelet activating factor in experimental allergic encephalomyelitis in rats. | 1989 | Agents Actions | pmid:2801340 |
Appleby P and Bowen JG | Cutaneous inflammatory disorders. | 1990 | Agents Actions | pmid:2117335 |
Lundgren JD et al. | Platelet activating factor and tracheobronchial respiratory glycoconjugate release in feline and human explants: involvement of the lipoxygenase pathway. | 1990 | Agents Actions | pmid:2117336 |
Doyle SA et al. | Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. | 1990 | Agents Actions | pmid:2178317 |
Nieminen MM et al. | Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. | 1991 | Agents Actions | pmid:1862740 |
Swingle KF and Reiter MJ | Inhibition of Paf-acether-induced edema of the rat's paw. | 1986 | Agents Actions | pmid:2875631 |
Flower RJ | Background and discovery of lipocortins. | 1986 | Agents Actions | pmid:2938452 |
Adnot S et al. | Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. | 1987 | Agents Actions | pmid:3115070 |
Montrucchio G et al. | The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. | 1987 | Agents Actions | pmid:3115072 |
Carlson RP et al. | Pharmacologic modulation of PAF-induced mortality in mice. | 1987 | Agents Actions | pmid:3120513 |
Cahill M et al. | Effect of des arginine9-bradykinin and other bradykinin fragments on the synthesis of prostacyclin and the binding of bradykinin by vascular cells in culture. | 1988 | Agents Actions | pmid:3051930 |
Cunha FQ et al. | Failure of PAF-acether to induce in vivo neutrophil migration. | 1988 | Agents Actions | pmid:3055873 |
Touvay C et al. | Inhibition of antigen-induced lung anaphylaxis in the guinea-pig by BN 52021 a new specific paf-acether receptor antagonist isolated from Ginkgo biloba. | 1986 | Agents Actions | pmid:3754380 |
Kusner EJ et al. | Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. | 1987 | Agents Actions | pmid:3577957 |
Archer CB et al. | Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether. | 1985 | Agents Actions | pmid:3923788 |
Pirotzky E et al. | Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. | 1985 | Agents Actions | pmid:4003192 |
Page CP et al. | Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. | 1985 | Agents Actions | pmid:4003195 |
Page CP et al. | Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. | 1985 | Agents Actions | pmid:4003196 |
Spicer BA et al. | An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. | 1985 | Agents Actions | pmid:4003197 |
Boughton-Smith NK et al. | Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. | 1992 | Agents Actions | pmid:1279960 |
Northover AM | In vitro effects of PAF on venous endothelial cell actin disposition. | 1992 | Agents Actions | pmid:1509977 |
Rachmilewitz D et al. | Cytokines and platelet-activating factor in human inflamed colonic mucosa. | 1992 | Agents Actions | pmid:1359744 |
Benveniste J | Platelet-activating factor (PAF-acether): present status. | 1981 | Agents Actions | pmid:6176101 |
Northover AM and Northover BJ | Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. | 1994 | Agents Actions | pmid:7942320 |
Tubaro E et al. | In vitro and in vivo impact of a new glycosphingolipid on neutrophils. | 1994 | Agents Actions | pmid:7879694 |
Canale P et al. | TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. | 1994 | Agents Actions | pmid:7879698 |
Thomas TK et al. | Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat. | 1993 | Agents Actions | pmid:8273566 |
Glaser KB et al. | Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). | 1993 | Agents Actions | pmid:8273577 |
Perret BA et al. | Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. | 1981 | Agents Actions | pmid:6803540 |
Denburg JA et al. | Platelet activating factor: regulation by mast cells and aspirin. | 1984 | Agents Actions | pmid:6711391 |
Lecrubier C et al. | Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. | 1983 | Agents Actions | pmid:6858789 |
Fouque F et al. | Platelet-activating factor (PAF-acether): thromboxane-independent synergism with adrenaline on human platelets and recent insights into its mode of action. | 1982 | Agents Actions | pmid:7164947 |
Lefort J et al. | Pharmacological properties of PAF-acether in the guinea-pig: platelet-dependent and independent reactions. | 1982 | Agents Actions | pmid:7164948 |
Heller R et al. | S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. | 1993 | Agents Actions | pmid:7517616 |
Izzo AA et al. | Platelet activating factor potentiates rat paw oedema induced by different phlogogen agents. | 1994 | Agents Actions | pmid:7524288 |
Lartigue-Mattei C et al. | Pharmacokinetic study of 3H-labelled PAF-acether II. Comparison with 3H-labelled lyso-PAF-acether after intravenous administration in the rabbit and protein binding. | 1984 | Agents Actions | pmid:6532184 |
Czarnetzki BM and Benveniste J | Effect of synthetic PAF-acether on human neutrophil function. | 1981 | Agents Actions | pmid:7041568 |
Camussi G et al. | Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). | 1981 | Agents Actions | pmid:7041569 |
de Bernardis E et al. | Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. | 1994 | Agents Actions | pmid:7847181 |
Kelefiotis D and Vakirtzi-Lemonias C | In vivo responses of mouse blood cells to platelet-activating factor (PAF): role of the mediators of anaphylaxis. | 1993 | Agents Actions | pmid:8023738 |
Northover AM and Northover BJ | Involvement of protein kinase C in the control of microvascular permeability to colloidal carbon. | 1993 | Agents Actions | pmid:8304240 |
Kurosawa M | Effect of platelet activating factor on histamine release from rat mast cells. | 1987 | Agents Actions Suppl. | pmid:2445185 |
König W et al. | On the biological role of lipid chemotactic factors. | 1983 | Agents Actions Suppl. | pmid:6404145 |
Vargaftig BB | Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. | 1983 | Agents Actions Suppl. | pmid:6575594 |